Category: CareFusion Corp.Syndicate content

Stryker may bid for Smith & Nephew following 6-month no-bid period | The week in medtech M&A

November 26, 2014 by MassDevice

Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Will Stryker bid on Smith & Nephew this week?: J&J demands $7.2 billion from Boston Scientific as trial begins; Will Orange County's medtech scene lose its juice without Allergan?; BD-CareFusion deal passes US anti-trust waiting period; Sources: Stryker weighs bid for Smith & Nephew

Will Stryker bid on Smith & Nephew this week?

November 24, 2014 by Brad Perriello

BD plans to use more cash, less debt for $12B CareFusion buy

November 25, 2014 by Brad Perriello

Becton Dickinson plans to cut the debt load from its $12 billion acquisition of CareFusion by some $1.4 billion after realizing it has more cash available that it thought.

BD plans to use more cash, less debt for $12B CareFusion buy

BD-CareFusion deal passes US anti-trust waiting period

November 21, 2014 by Mark Hollmer

Becton Dickinson's $12.2 billion bid for device maker CareFusion clears the required waiting period under U.S. anti-trust regulations.

BD-CareFusion deal passes US anti-trust waiting period

CareFusion's Q1 sales, earnings rise

November 7, 2014 by Brad Perriello

Sales and earnings rise during the fiscal 1st quarter for CareFusion as it prepares to be absorbed by Becton, Dickinson & Co.

CareFusion's Q1 sales, earnings rise

CareFusion (NYSE:CFN) ended its last fiscal quarter as a public company on a strong note, posting earnings growth of 2.8% on a top-line gain of 11.1%.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Edwards Lifesciences is back in Wall Street's good graces | Medtech Wall Street news for the week of October 6, 2014

October 9, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Wall Street loves Edwards Lifesciences again; Becton Dickinson to buy CareFusion for $12 billion in cash, stock; Proxy war rages on at Echo Therapeutics; Platinum fires back at Echo Therapeutics over 'rogue' directors; Echo Therapeutics hits back at Platinum Equity

Wall Street loves Edwards Lifesciences again

October 3, 2014 by Brian Johnson

Edwards: Medtronic TAVI settlement boosts bottom line in Q2

AdvaMed in the age of consolidation

October 6, 2014 by Brian Johnson

What does news of yet another mega-merger mean for medtech's industry council?

regular_avm14_press_conference_photo.jpg

The winds of change in medtech are blowing in the Windy City.

As medtech's best & brightest descended on Chicago for another annual confab at AdvaMed 2014, it was impossible to ignore that the industry has now entered the great age of consolidation with yet another multibillion-dollar healthcare deal.

Becton Dickinson to buy CareFusion for $12 billion in cash, stock

October 6, 2014 by MassDevice

Becton Dickinson & Co. agrees to pay $12 billion in cash and stock for CareFusion Corp.

Becton Dickinson to buy CareFusion for $12 billion in cash, stock

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp